Payment overview · 2025
General Payments
$671,533.57
90 reported records · 13 companies
Healthcare provider profile · identity verified
S. Samuel Bederman, M.D.
Allopathic & Osteopathic Physicians|Orthopaedic Surgery|Orthopaedic Surgery of the Spine · ORANGE, CA · NPI 1316190085
Verified facts
What the public records show
CMS Open Payments records show S. Samuel Bederman, M.D. received $671,533.57 in general payments during 2025 across 90 reported records.
Alphatec Spine, Inc accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tymlos.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alphatec Spine, Inc | Unresolved — no canonical attribution shown | $355,002.67 | 52.9% | 4 | 2025 |
| Spineart SA | Unresolved — no canonical attribution shown | $277,583.00 | 41.3% | 6 | 2025 |
| KYOCERA MEDICAL TECHNOLOGIES, INC. | Unresolved — no canonical attribution shown | $24,425.00 | 3.6% | 1 | 2025 |
| Spineart USA Inc | Unresolved — no canonical attribution shown | $12,049.77 | 1.8% | 19 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $839.13 | 0.1% | 24 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $750.25 | 0.1% | 5 | 2025 |
| Intrinsic Therapeutics | Unresolved — no canonical attribution shown | $224.23 | 0.0% | 7 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $218.15 | 0.0% | 4 | 2025 |
| Providence Medical Technology, Inc. | Unresolved — no canonical attribution shown | $191.78 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.57 | 0.0% | 15 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $51.31 | 0.0% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.18 | 0.0% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $18.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $632,585.67 | 10 |
| Consulting Fee | $32,271.00 | 4 |
| Travel and Lodging | $4,496.21 | 6 |
| Food and Beverage | $2,180.69 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Other - Miscellaneous Normalized: other miscellaneous |
Device | Alphatec Spine, Inc | $355,002.67 | 4 | 2025 |
Source payment records
|
|||||
| PERLA TL - DEGENERATIVE SCREW Normalized: perla tl degenerative screw |
Device | Spineart SA | $143,200.00 | 2 | 2025 |
Source payment records
|
|||||
| ROMEO2 - THORACOLUMBAR FIXATION Normalized: romeo2 thoracolumbar fixation |
Device | Spineart SA | $78,003.00 | 2 | 2025 |
Source payment records
|
|||||
| JULIET LL - LATERAL CAGE TI-LIFE Normalized: juliet ll lateral cage ti life |
Device | Spineart SA | $56,380.00 | 2 | 2025 |
Source payment records
|
|||||
| MISCELLANEOUS Normalized: miscellaneous |
Device | Orthofix Medical, Inc. | $596.00 | 1 | 2025 |
Source payment records
|
|||||
| CREO Normalized: creo |
Device | Globus Medical, Inc. | $225.58 | 3 | 2025 |
Source payment records
|
|||||
| BARRICAID ACD (ANNULAR CLOSURE DEVICE) Normalized: barricaid acd annular closure device |
Device | Intrinsic Therapeutics | $224.23 | 7 | 2025 |
Source payment records
|
|||||
| CODMAN CERTAS Normalized: codman certas |
Device | Integra LifeSciences Corporation | $218.15 | 4 | 2025 |
Source payment records
|
|||||
| CODMAN HAKIM Normalized: codman hakim |
Device | Integra LifeSciences Corporation | $218.15 | 4 | 2025 |
Source payment records
|
|||||
| CUSA CLARITY Normalized: cusa clarity |
Device | Integra LifeSciences Corporation | $218.15 | 4 | 2025 |
Source payment records
|
|||||
| DuraSeal Exact Spinal Sealant System Normalized: duraseal exact spinal sealant system |
Device | Integra LifeSciences Corporation | $218.15 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $156.57 | 15 | 2025 |
Source payment records
|
|||||
| NorthStar Normalized: northstar |
Device | Orthofix Medical, Inc. | $94.06 | 1 | 2025 |
Source payment records
|
|||||
| Perla TL Normalized: perla tl |
Device | Spineart USA Inc | $84.82 | 3 | 2025 |
Source payment records
|
|||||
| ALVUE Normalized: alvue |
Device | Globus Medical, Inc. | $71.95 | 2 | 2025 |
Source payment records
|
|||||
| ELSA Normalized: elsa |
Device | Globus Medical, Inc. | $68.68 | 2 | 2025 |
Source payment records
|
|||||
| STRETTO Normalized: stretto |
Device | Globus Medical, Inc. | $63.23 | 2 | 2025 |
Source payment records
|
|||||
| Lattus Normalized: lattus |
Device | Orthofix Medical, Inc. | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| PERLA C Normalized: perla c |
Device | Spineart USA Inc | $54.96 | 2 | 2025 |
Source payment records
|
|||||
| CALIBER Normalized: caliber |
Device | Globus Medical, Inc. | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $51.31 | 2 | 2025 |
Source payment records
|
|||||
| COLOSSEUM Normalized: colosseum |
Device | Globus Medical, Inc. | $47.60 | 1 | 2025 |
Source payment records
|
|||||
| CANOPY Normalized: canopy |
Device | Globus Medical, Inc. | $47.02 | 2 | 2025 |
Source payment records
|
|||||
| CITADEL Normalized: citadel |
Device | Globus Medical, Inc. | $43.53 | 1 | 2025 |
Source payment records
|
|||||
| COALITION AGX Normalized: coalition agx |
Device | Globus Medical, Inc. | $42.68 | 2 | 2025 |
Source payment records
|
|||||
| AERIAL Normalized: aerial |
Device | Globus Medical, Inc. | $41.79 | 1 | 2025 |
Source payment records
|
|||||
| MARS Normalized: mars |
Device | Globus Medical, Inc. | $37.47 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.70 | 3 | 2025 |
Source payment records
|
|||||
| ACADIA Normalized: acadia |
Device | Globus Medical, Inc. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| FLEXUS Normalized: flexus |
Device | Globus Medical, Inc. | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| ASSURE Normalized: assure |
Device | Globus Medical, Inc. | $21.00 | 2 | 2025 |
Source payment records
|
|||||
| SCARLET AL-T Normalized: scarlet al t |
Device | Spineart USA Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| ALTERA Normalized: altera |
Device | Globus Medical, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Tymlos tymlos |
2025 | Tymlos | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 126 | 53 |
| Tramadol Hcl | Tramadol Hcl | 68 | 34 |
| Methylprednisolone | Methylprednisolone | 48 | 47 |
| Naproxen | Naproxen | 43 | 31 |
| Pregabalin | Pregabalin | 41 | 21 |
| Tymlos | Abaloparatide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 13 |
| Diazepam | Diazepam | 21 | 20 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 18 |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $671,533.57 · 90 records | Alphatec Spine, Inc | ACADIA, AERIAL, ALTERA, ALVUE, ASSURE, BARRICAID ACD (ANNULAR CLOSURE DEVICE), CALIBER, CANOPY, CITADEL, COALITION AGX, CODMAN CERTAS, CODMAN HAKIM, COLOSSEUM, CREO, CUSA CLARITY, DuraSeal Exact Spinal Sealant System, ELSA, EVENITY, FLEXUS, JULIET LL - LATERAL CAGE TI-LIFE, Lattus, MARS, MISCELLANEOUS, Nalu Neurostimulation System, NorthStar, Other - Miscellaneous, PERLA C, PERLA TL - DEGENERATIVE SCREW, PROLIA, Perla TL, ROMEO2 - THORACOLUMBAR FIXATION, SCARLET AL-T, STRETTO, Tymlos, Xeomin | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tymlos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Radius Health, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error